Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder

European Urology

Volumn 72, Issue 4, 2017, Pages 483-487

  Seisen, Thomas ^a   Sun, Maxine ^a   Lipsitz, Stuart R ^a   Abdollah, Firas ^b   Leow, Jeffrey J ^a   Menon, Mani ^b   Preston, Mark A ^a   Harshman, Lauren C ^c   Kibel, Adam S ^a   Nguyen, Paul L ^a   Bellmunt, Joaquim ^c   Choueiri, Toni K ^c   Trinh, Quoc Dien ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cystectomy; Drug therapy; Propensity score; Radiotherapy; Survival; Urinary bladder neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER PATIENT; CANCER RADIOTHERAPY; CHARLSON COMORBIDITY INDEX; CHEMORADIOTHERAPY; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYSTECTOMY; DATA BASE; FEMALE; HAZARD RATIO; HUMAN; INVERSE PROBABILITY OF TREATMENT WEIGHTING; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MUSCLE INVASIVE BLADDER CANCER; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURGICAL RISK; TIME; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; ADJUVANT CHEMORADIOTHERAPY; BLADDER TUMOR; CANCER STAGING; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PATHOLOGY; RISK FACTOR; SMOOTH MUSCLE; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; TUMOR INVASION; UROTHELIUM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY, ADJUVANT; COMPARATIVE EFFECTIVENESS RESEARCH; CYSTECTOMY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUSCLE, SMOOTH; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 85017434132     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2017.03.038     Document Type: Article

References (10)

1. Ploussard, G., Daneshmand, S., Efstathiou, J.A., et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol 66 (2014), 120–137.
2. Paramasivan, S., Huddart, R., Hall, E., Lewis, R., Birtle, A., Donovan, J.L., Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011). Trials, 12, 2011, 78.
3. Bekelman, J.E., Handorf, E.A., Guzzo, T., et al. Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification bias in cancer observational comparative effectiveness research. Value Health 16 (2013), 610–618.
4. Smith, A.B., Deal, A.M., Woods, M.E., et al. Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base. BJU Int 114 (2014), 719–726.
5. Gofrit, O.N., Nof, R., Meirovitz, A., et al. Radical cystectomy vs. chemoradiation in T2-4aN0M0 bladder cancer: a case-control study. Urol Oncol, 33, 2015 19.e1-5.
6. Austin, P.C., An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46 (2011), 399–424.
7. Fisher, L.D., Lin, D.Y., Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 20 (1999), 145–157.
8. James, N.D., Hussain, S.A., Hall, E., et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366 (2012), 1477–1488.
9. Advanced Bladder Cancer Overview Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev, 2005, 2005 CD005246.
10. Mak, K.S., Smith, A.B., Eidelman, A., et al. Quality of Life in long-term survivors of muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 96 (2016), 1028–1036.